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Background: Cellular models of muscle disease are taking on increasing importance with the large number of
genes and mutations implicated in causing myopathies and the concomitant need to test personalized therapies.
Developing cell models relies on having an easily obtained source of cells, and if the cells are not derived from
muscle itself, a robust reprogramming process is needed. Fibroblasts are a human cell source that works well
for the generation of induced pluripotent stem cells, which can then be differentiated into cardiomyocyte
lineages, and with less efficiency, skeletal muscle-like lineages. Alternatively, direct reprogramming with the
transcription factor MyoD has been used to generate myotubes from cultured human fibroblasts. Although
useful, fibroblasts require a skin biopsy to obtain and this can limit their access, especially from pediatric
populations.
Results: We now demonstrate that direct reprogramming of urine-derived cells is a highly efficient and reproducible
process that can be used to establish human myogenic cells. We show that this method can be applied to urine cells
derived from normal individuals as well as those with muscle diseases. Furthermore, we show that urine-derived cells
can be edited using CRISPR/Cas9 technology.
Conclusions: With progress in understanding the molecular etiology of human muscle diseases, having a readily
available, noninvasive source of cells from which to generate muscle-like cells is highly useful.
Keywords: Urine cells, MyoD, Reprogramming, Myotubes, Muscular dystrophy, CRISPRBackground
The genetic diversity of muscle diseases, including the
muscular dystrophies, is extensive [1, 2]. Defining
underlying mechanisms and developing therapies to
correct these defects require appropriate models of
disease. Animal models offer in vivo insight and have
proved highly useful, but animal models are time
consuming and costly to develop and cannot represent
the large number of alleles responsible for muscle
diseases. Cellular models of disease have expanded in
recent years with significant advances in reprogram-
ming and the creation of induced pluripotent stem cells
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than skeletal myocytes, from iPSCs has led to this
cell type being used as a surrogate for skeletal muscle
[3–5]. Although progress has been made in generating
muscle-like lineages from iPSCs, this process is still
time-consuming and has variable outcomes within and
across culture systems [6, 7]. Other commonly used
cell models of skeletal muscles include the mouse
C2C12, rat L6, and human myoblast cell lines, which
undergo differentiation into multinucleate myotubes
under appropriate conditions [8, 9]. These myoblast
models have been highly useful for the field but repre-
sent normal skeletal muscle and not disease-specific
conditions. While myoblasts can be cultured from
human muscle, biopsies from patients are invasive and
at times problematic for those with muscle mass-
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pathogenesis and testing potential drugs.
Direct reprogramming of fibroblasts with MyoD into
myotubes was a central experiment used to demonstrate
the role of transcription factors [10, 11]. Since that ori-
ginal observation, MyoD delivery into fibroblasts has
been optimized using viral vectors and this method can
be applied to make directly reprogrammed myogenic
cells from humans and mice [12, 13]. A fusion between
MyoD and the estrogen receptor was generated to create
a tamoxifen-inducible MyoD, and this construct was
used in mouse and human fibroblasts to induce myogen-
esis [14–16]. Thus, direct reprogramming of fibroblasts
remains a highly useful method for modeling human
muscle diseases. However, dermal fibroblasts are ob-
tained through skin biopsy, and the invasive nature of
skin biopsy, while considerably less than muscle biopsy,
can be particularly problematic in children.
One potential noninvasive source of patient-specific
cells is cells isolated from urine. It has been estimated
that about 2000 to 7000 renal tubular epithelial cells are
shed in urine everyday [17, 18]. Obtaining a urine sam-
ple is noninvasive, making urine a good source of cells,
especially from children. Urine cells have been isolated
from both healthy volunteers and patients of a wide age
range [18–21]. Urine-derived cells (UDCs) are thought
to be of a mixed population that originates from either
the renal epithelium or the uroepithelium [18, 21]. Inter-
estingly, a subset of UDCs has been observed to carry
mesenchymal stem cell markers as well as low endogen-
ous expression of Oct3/4, a pluripotency marker [4, 20, 22].
As such, UDCs demonstrate propensity for differenti-
ation into several lineages, one of which is muscle-like
[20, 23].
We show here that UDCs serve as a noninvasive
source for MyoD-induced myogenesis. UDCs transduced
with a tamoxifen-inducible MyoD lentiviral vector
(iMyoD) formed multinucleate myotubes following in-
duction with tamoxifen and culture in differentiation
media for up to 35 days. Urine cell-derived myotubes
expressed muscle marker transcripts, formed sarco-
meres, and displayed contractile properties. Further,
UDCs isolated from individuals with muscular dystro-
phies were also able to form myotube-like structures
and reflected the disease mutations. Thus, UDCs are a
ready source for direct reprogramming by MyoD and
provide an easily obtainable, noninvasive source for
modeling disease mechanisms.
Methods
Urine collection and cell isolation
Written and informed consent was obtained from all
human subjects. All work was approved by and con-
ducted under the Institutional Review Boards of theUniversity of Chicago (IRB8249) and Northwestern
University (IRB STU00104548), which serve as the
ethics boards for each institution, respectively. All
studies were conducted in compliance with the
Helsinki Declaration. Urine samples were collected
using midstream clean catch kits according to the
directions provided in the kits (Parter Medical Prod-
ucts Inc, Carson, CA; 273516). Cells were isolated
within 1 h of collection using a protocol previously
published with minor modifications [24]. Briefly, the
entire urine samples were equally distributed into 50-
mL conical tubes and centrifuged at 400×g for 10 min
at room temperature. The supernatant was aspirated
leaving ~1 mL of urine into which pellets were resus-
pended and combined into a single tube, if necessary.
Ten milliliters of wash buffer was added per 100 mL of
initial urine sample. Samples were centrifuged at
200×g for 10 min at room temperature. The super-
natant was aspirated leaving ~0.2 mL, and the cell pel-
let was resuspended in 1 mL of primary media. All
media formulations were obtained from a previously
published protocol and are detailed below [24]. Cells
were plated in 24-well plates pre-coated with 0.1 % gel-
atin (Millipore, Billerica, MA; ES-006-B, Stemcell
Technologies, Vancouver, Canada; 7903). Roughly one
third of the cell suspension was plated in the first well,
with the remaining two thirds equally divided into four
additional wells. The final volume in each well was
then brought to 500 μL with primary media. The plates
were placed in a 37 °C incubator with 5 % CO2.
For 3 days, 500 μL of primary media was added to
each well every 24 h. On day 4, 1.5 mL of primary
media was removed and replaced with 500 μL of pro-
liferation media. An aliquot of the primary media was
added to a separate dish containing Dulbecco’s Modi-
fied Eagle Medium (DMEM) supplemented with 10 %
FBS without antibiotics or antimycotics to test for
potential contamination. On day 5, all media were
removed from each well and replaced with 500 μL of
proliferation media, which was changed daily until
the isolated cells expanded and were replated in
larger dishes. Antibiotics and antimycotics were re-
moved from media once uncontaminated cultures
were confirmed. Isolated cells were observed as early
as 1 day after the addition of proliferation media.
When the cells became confluent or when cell foci
began to outgrow the monolayer, cells were trypsi-
nized using 0.25 % trypsin-EDTA (Thermo Fisher
Scientific, Waltham, MA; 25200-072), subcultured,
and designated as passage 1 (p1). Modifications from
[24] include plating of cells in five wells of a 24-well
gelatin-coated plate (vs a single well of 12-well plate),
increase of FBS content in the proliferation media to
15 %, and the removal of the antimycotics and
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ation was observed.Media composition
All media were made following a previously published
protocol with the following modifications [24]. Wash
buffer consisted of 1× phosphate-buffered saline (PBS)
without Ca2+ and Mg2+ (Thermo Fisher Scientific,
Waltham, MA; 14190-250) supplemented with 1 % peni-
cillin/streptomycin (Thermo Fisher Scientific, Waltham,
MA; 15070-063) and 0.5 μg/mL amphotericin B
(Sigma Aldrich, St. Louis, MO; A2942). Primary media
were composed of 1:1 mix of high glucose DMEM
without sodium pyruvate (GE Healthcare, Logan, UT;
SH30022.FS) and Ham’s F-12 Nutrient Mix (Thermo
Fisher Scientific, Waltham MA; 11765-054) supple-
mented with Renal Epithelium Growth Medium Single-
Quot Kit Supplements (Lonza, Basel, Switzerland;
CC-4127), 10 % fetal bovine serum (Thermo Fisher
Scientific, Waltham, MA; 16000-044), 1 % penicillin/
streptomycin, and 0.5 μg/mL amphotericin B. Prolifera-
tion media were composed of 1:1 mix of Renal
Epithelium Growth Medium Bullet Kit (Lonza, Basel,
Switzerland; CC-3190) and high glucose DMEM supple-
mented with 15 % FBS, 0.5 % Glutamax (Thermo Fisher
Scientific, Waltham, MA; 35050-061), 0.5 % nonessential
amino acids (Thermo Fisher Scientific, Waltham, MA;
11140-050), and 2.5 ng/mL of bFGF (Peprotech, Rocky
Hill, NJ; 100-18B, Miltenyi Biotec Inc, San Diego, CA;
130-093-842), PDGF-AB (Peprotech, Rocky Hill, NJ;
100-00AB), and EGF (Peprotech, Rocky Hill, NJ;
AF-100-15). The Renal Epithelium Growth Medium
(REGM) Bullet Kit was made according to the manufac-
turer’s instructions, with the omission of the ampho-
tericin B/gentamycin supplement. Freeze media were
composed of DMEM (Thermo Fisher Scientific,
Waltham, MA; 11995-073) supplemented with 30 %
FBS, 1x pen/strep, and 10 % DMSO (Sigma Aldrich, St.
Louis, MO; D2650).Lentiviral construct and transduction
The tamoxifen-inducible MyoD lentiviral construct
(pLv-CMV-MyoD-ER(T)), referred to as iMyoD, was
previously described [14] and kindly provided by
Dr. Jeffrey Chamberlain (University of Washington;
Addgene plasmid # 26809). The construct was pack-
aged by the Skin Disease Research Center DNA/RNA
Delivery Core at Northwestern University (Chicago,
IL). Urine cells from healthy volunteers or patients
were plated in 12-well plates at 75,000 cells/well and
transduced within 24–36 h of plating with iMyoD at
MOI = 50. Transductions were performed in prolifera-
tion media with reduced serum (5 %) and 7.5 μg/mLpolybrene (Millipore, Billerica, MA; TR-1003-G) for 6–16 h
in a 37 °C incubator.
Evaluation of transduction efficiency
After transduction, an aliquot of cells were plated in
two wells of a 24-well plate at 2000–10000 cells/cm2.
Cells were treated with 5 μM 4-hydroxytamoxifen
(Sigma Aldrich, St. Louis, MO; H7904) for 24 to 48 h,
and MyoD was detected using immunofluorescence.
Methods and antibodies are as described below. A
minimum of three fields and a minimum of 100 cells
total were analyzed to determine transduction effi-
ciency. MyoD-positive nuclei and total nuclei were
counted per field, and efficiency was calculated by div-
iding the number of MyoD-positive nuclei by the total
number of nuclei per field. Efficiencies were graphed as
mean ± standard error of the mean (SEM) using Graph-
Pad Prism (GraphPad, La Jolla, CA). All images were
taken using the Floid Cell Imaging Station (Thermo
Fisher Scientific, Waltham, MA; 4471136). The cell
counts for MyoD-positive nuclei were performed
manually using ImageJ (NIH, Bethesda, MD), while the
cell counts for total nuclei were performed using the
Particle Analyzer function of ImageJ (NIH, Bethesda,
MD).
Myogenic differentiation
Transduced cells were plated in 24-well plates coated
with 8 μg/cm2 collagen I (Sigma Aldrich, St. Louis, MO;
C3867, Corning, Corning, NY; 354236) at a density of
37,500 to 50,000 cells/cm2 and cultured until confluent.
Cells were then overlaid with Growth Factor Reduced
Matrigel (Corning, Corning, NY; 354230) diluted 1:4 in
cold DMEM/F-12 50:50 mix (Corning, Corning, NY;
10-092-CV). Matrigel was allowed to gel for 2 to 3 hours
at 37 °C. The Matrigel-overlaid iMyoD-treated cells
were induced with 4-hydroxytamoxifen (2.5 μM, 24–
48 h) diluted in high glucose DMEM (Thermo Fisher
Scientific, Waltham, MA; 11995-073) supplemented
with 10 % FBS. Hydrocortisone dexamethasone (HD)
differentiation media were based on previously pub-
lished formulation [23, 25] and were composed of high
glucose DMEM with sodium pyruvate supplemented
with 10 % FBS, 5 % horse serum (Thermo Fisher Scien-
tific, Waltham, MA; 16050-122), 50 μM hydrocortisone
(Sigma Aldrich, St. Louis, MO; H0888), and 0.1 μM
dexamethasone (Sigma Aldrich, St. Louis, MO; D4902).
Two hundred and fifty microliters of differentiation
media was replaced every 72 h. Additional coatings
tested during plating optimization included collagen IV
(Sigma Aldrich, St. Louis, MO; C5533), fibronectin
(Sigma Aldrich, St. Louis, MO; F1141), laminin (Sigma
Aldrich, St. Louis, MO; L2020), Growth Factor Reduced
Matrigel, poly-L-lysine (Sigma Aldrich, St. Louis, MO;
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RNA analysis
Differentiated myotubes were collected at three different
time points (7, 14, and 28 days). Cells were gently
washed with cold 1× PBS. Washes were repeated until
most of the Matrigel was removed. RNA was isolated in
TRIzol (Thermo Fisher Scientific, Waltham, MA; 15596-
018) following the manufacturer’s instructions. Glycogen
(Thermo Fisher Scientific, Waltham, MA; AM9510) was
added at 50–100 μg/mL to the isopropanol before RNA
precipitation. RNA concentration was determined using
NanoDrop 2000 (Thermo Fisher Scientific, Waltham,
MA). RNA (1000–1500 ng) was reverse transcribed
using qScript cDNA SuperMix (Quanta Biosciences,
Gaithersburg, MD; 95048-025). Complementary DNA
(cDNA) (30–50 ng) was used per PCR reaction, and the
products were separated on 1.5 % agarose gel with eth-
idium bromide. Gels were visualized and imaged on the
UVP Transilluminator (UVP, Upland, CA). Quantitative
PCR was performed with 30–50 ng of cDNA using iTaq
Universal SYBR Green Supermix (Bio-Rad, Hercules,
CA; 1725124) with biological triplicates when avail-
able and technical duplicates. Cq values were aver-
aged for each pair of technical duplicates and
normalized to GAPDH. ΔCq values were calculated
as Cq(gene of interest)—Cq(GAPDH), and ΔΔCq values
were calculated as 2^(−ΔCq). ΔΔCq values were then
multiplied by 1000 as an arbitrary factor for graphing
purposes. ΔΔCq values were graphed as mean ± SEM
using GraphPad Prism (GraphPad, La Jolla, CA).
Primers used for RT- and qRT-PCR are listed in
Tables 1 and 2.
Immunofluorescence microscopy
Differentiated myotubes were subject to immunofluores-
cence microscopy at four different time points (7, 14, 28,
and 35 days). Myotubes were gently washed with 1× PBS
(Thermo Fisher Scientific, Waltham, MA; 14200-166)
three times, or until most of the Matrigel was removed,
and then fixed in either 4 % paraformaldehyde (15 min
at RT) or ice cold 100 % methanol (2 min on ice). Myo-
tubes fixed in paraformaldehyde were subsequently
permeabilized in 0.25 % Triton-X (Sigma Aldrich, St.
Louis, MO; T8787) for 20 min at RT. Cells were blocked
in 10 % horse serum for 30 min to 1 h at 4 °C. Primary
antibody incubations were done overnight at 4 °C. Cells
were washed three times for 10 min each with PBS,
where PBS was supplemented with 0.1 % Triton-X in the
second wash. Cells were incubated with secondary anti-
bodies (1 h at RT) and then washed three times for
10 min each as described above. Nuclei were stained
with Hoechst 33342 (1:10,000, Thermo Fisher Scientific,Waltham, MA; H3570). Plates were imaged on the Zeiss
Axio Observer Z.1 inverted microscope (Carl Zeiss
Microscopy, Jena, Germany) and/or Floid Cell Imaging
Station. All antibodies were diluted in 0.1 % Triton-X and
2 % horse serum, and all solutions were made with 1× PBS.Antibodies
Primary antibodies were as follows: rabbit polyclonal
anti-MyoD (1:1000, Santa Cruz, Dallas, TX; sc-304),
mouse monoclonal anti-desmin (1: 1000, Sigma Aldrich,
St. Louis, MO; D1033), mouse monoclonal anti-α-
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rabbit polyclonal anti-dystrophin (1: 1000, Thermo
Fisher Scientific, Waltham, MA; PA1-37587), mouse
monoclonal anti-dystrophin (1: 100, Leica Biosystems,
Newcastle, UK; NCL-DYSB), mouse monoclonal anti-
MYH1 (1: 10 or 2 μg/mL, deposited to Developmental
Studies Hybridoma Bank by Fischman, DA; MF 20),
mouse monoclonal anti-fast myosin heavy chain (1:
1000, Sigma Aldrich, St. Louis, MO; M4276), mouse
monoclonal anti-titin antibody (1: 10 or 2 μg/mL,
deposited to Developmental Studies Hybridoma Bank
by Greaser, ML; 9 D10), and rabbit polyclonal anti-γ-
sarcoglycan (1: 300 to 1: 500 [26]). Secondary
antibodies were as follows: Alexa Fluor 488 donkey
anti-rabbit (1: 1,1000; A21206), Alexa Fluor 488 don-
key anti-mouse (1: 1000; A21202), Alexa Fluor 594
donkey anti-rabbit (1: 1000; A21207), and Alexa Fluor
594 donkey anti-mouse (1: 1,1000; A21203, all
Thermo Fisher Scientific, Waltham, MA).
Sequencing
DMD exons 42 through the junction of exons 50 and 51
were amplified by PCR, gel purified using QIAEXII Gel
Extraction Kit (Qiagen, Valencia, CA; 20021). The
purified products were amplified by PCR using nested
primers for DMD exons 44 through 48 and then se-
quenced at the NUSeq Core at Northwestern University
(Chicago, IL). Chromatograms and sequences were
analyzed on SeqMan Pro (DNASTAR, Madison, WI) and
FinchTV (Geospiza, Seattle, WA).
CRISPR/Cas9 design
To generate a point mutation in control urine cells, we
used the Cas9-GFP plasmid designed by the Zhang lab
(Addgene plasmid #48138) [27]. The CRISPR design tool
(crispr.mit.edu) was used to identify and select guide RNA
(gRNA) targets in human SGCG exon 6. The target on
the anti-sense strand was gRNA 5′ CTAAGGTCTT
GAAACGGGT 3′. This guide permitted a synonymous
mutation of the protospacer adjacent motif (PAM) and
preserved the 5′ SGCG exon 6 sequence. The gRNA was
expressed from the U6 polymerase III promoter as
previously described [28]. The promoter, crRNA-tracrRNA,
and target were synthesized as a gBlock by Integrated DNA
Technologies (IDT, Coralville, IA), then PCR amplified
(F: TGTACAAAAAAGCAGGCTTTAAAG; R: TAATGC-
CAACTTTGTACAAGAAAG), and purified using the
Qiagen PCR purification kit (Qiagen, Valencia, CA; 28106).
The single-stranded oligodeoxynucleotide (ssODN) was de-
signed according to published guidelines [29]. The ssODN,
based on the anti-sense strand template, was centered in
between the nuclease site and the desired thymine deletion
with 71 bp flanking arms on either side (142 bp total). It
contained a downstream G >A synonymous mutationthat destroyed the PAM –NGG site (CGG > CAG).




and PAGE purified by IDT. Uppercase letters indicate the
SGCG exon 6 coding region, and lowercase letters indicate
the flanking intronic regions. The single underlined region
encodes the targeted mutation of the protospacer adjacent
motif (PAM), and the italicized sequence is the 4 adenine
(AAAA) sequence which encodes the single thymine
(T) deletion in the exon 6 coding region.Electroporation with CRISPR reagents
On the day of electroporation, urine cells were trypsi-
nized, centrifuged at 400×g for 5 min (RT), and resus-
pended in PBS. An aliquot was removed for cell
counting, and cells were centrifuged at 400×g for 5 min
(RT). Cells were resuspended in electroporation buffer
1 × 106 cells/mL (Bio-Rad, Hercules, CA; 165-2677) and
2 × 105 cells were added to the Cas9 GFP plasmid (1 μg),
U6 gRNA (500 ng), and ssODN (0.5 nmol) reagents.
After gentle mixing, the cells were placed in a sterile
cuvette with a 0.4-cm gap (Bio-Rad, Hercules, CA;
1652088) and electroporated using Gene Pulser Xcell
Electroporation System (Bio-Rad, Hercules, CA; 1652660)
with the following settings: (1) single square wave pulse,
200 V, 20 msec or (2) three square waves pulses, 150 V,
20 msec (0.1 s between pulses). The electroporated cells
were added to gelatin-coated six-well plates and brought to
a final volume of 2 mL with proliferation media. The media
were replaced within 12 h and replaced every 24 h for
3–5 days until fluorescence-activated cells sorting (FACS).FACS sorting and clonal expansion
Prior to cell sorting, 96-well plates were pre-coated with
0.1 % gelatin and placed in the incubator for 1 h. Gelatin
was removed and replaced with 100 μL of proliferation
media that were supplemented with 0.5× pen/strep. The
electroporated cells were trypsinized, centrifuged, and
resuspended in 1 mL of proliferation media supple-
mented with 0.5× pen/strep. Single cell sorting of GFP-
positive cells into 96-well plates was conducted by the
Northwestern Flow Cytometry Facility using the FACS
AriaII (BD Biosciences, San Jose, CA). After sorting,
96-well plates were briefly centrifuged at 200×g for
1 min (RT) and placed in a 37 °C incubator. After
48 h, 100 μL of proliferation media without pen/strep
was added to the 96-well plates. A complete media
exchange was performed on days 4, 8, and 12 using
proliferation media without pen/strep. Expansion
of single cell clones was evident 7–10 days after
FACS, with confluent wells observed about day 14.
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24-well plates until confluent and then subcultured
onto gelatin-coated six-well plates.
Genotype analysis of clones
Clones expanded to the six-well stage were analyzed for
genome editing via the CRISPR/Cas9 system. Genomic
DNA was isolated and PCR amplified using the GeneArt
cleavage detection kit (Thermo Fisher Scientific, Wal-
tham, MA; A24372) according to the manufacturers’ in-
structions. The primer set amplified a genomic region
containing SGCG exon 6 along with a portion of
the flanking introns (F: TAGGGAAAGAGTTGGGCC-
TATTT) (R: GAGGCAGATTGGAGAGGAAGAA). To
test for clones edited through homology-dependent re-
pair (HDR), PCR-amplified products were subjected to
Alu1 digest and restriction fragment length polymorph-
ism (RFLP) analysis. In addition, PCR products from in-
dividual clones were sequenced at the NUSeq Core at
Northwestern University (Chicago, IL). Chromatograms
and sequences were analyzed using SeqMan Pro (DNAS-
TAR, Madison, WI).
Results
Generation of urine-derived cells with inducible MyoD
expression
Urine-derived cells were previously shown to be a useful
source for the generation of iPSCs [30]. To test direct
reprogramming into myogenic lineages using urine cells,
we used viral delivery of the muscle transcription factor
MyoD. We used a previously characterized tamoxifen-
inducible MyoD (iMyoD) lentivirus, which permits the
culture and expansion of cells in an undifferentiated
state until a reprogramming start point is determined
[14]. The procedure includes urine cell isolation, prolif-
eration, iMyoD transduction, tamoxifen induction, myo-
genic differentiation, and evaluation (Fig. 1a). Urine was
isolated from multiple healthy individuals (n > 8), and
urine cells were isolated and cultured as described
[22, 24]. Bright-field images from two typical urine
cultures demonstrated characteristic urine cell morph-
ology and growth (Fig. 1b). More than one cellular
morphology was noted, and independent cultures
from the same individual were observed to have dif-
ferential growth rates. In general, we selected clones
demonstrating rapid expansion and displaying a type
1 morphology, characterized as a monolayer of polar
cells with a “rice-grain” appearance, that maintained
close cell-cell contact [19, 31, 32]. Both fresh and
freeze-thawed urine cells were used for lentiviral
transduction with success.
Urine cells were transduced with the iMyoD lenti-
virus, regularly achieving >80 % efficiency with an
MOI of 50, as determined by immunofluorescencemicroscopy and image analysis for MyoD expression
(Fig. 1c, d). In the absence of tamoxifen, MyoD was
seen in cytoplasm. After tamoxifen exposure, MyoD
staining also became nuclear (Fig. 1c). Because lenti-
viral transduction was of such high efficiency, nuclear
MyoD staining was routinely evident in 80 % of the cul-
tures (Fig. 1d).
Morphological and molecular myogenic reprogramming
of iMyoD urine-derived cells
After iMyoD transduction, urine cells underwent testing
for myogenic reprogramming with or without tamoxifen
followed by culture in differentiation media (HD media),
a formulation previously shown to enhance the en-
dogenous myogenic potential of untransduced urine
cells [23]. RT-PCR amplification showed upregulation
of the DES (desmin) transcript in tamoxifen-treated
cells by the 7-day (7d) time point, and this was
sustained throughout the differentiation time course
(Fig. 2a). Low-level DES expression was detected in
uninduced iMyoD urine cells cultured in HD media
alone (Fig. 2a, b). Immunofluorescence microscopy
showed that desmin protein expression was evident in
tamoxifen-induced iMyoD cells at the earliest time
point (7d) and increased with extended culture in HD
differentiation media (Fig. 2c, d). Desmin protein
expression was observed concomitant with increased
myotube organization and elongation (Fig. 2c, d).
Desmin protein expression was not readily evident in
uninduced iMyoD cells (Fig. 2c).
Myogenic differentiation and maturation
We assessed myotube differentiation on alternative
coated surfaces including collagen, laminin, fibronec-
tin, or poly-lysine. We also assessed the effectiveness
of Matrigel overlay. We found that matrigel overlay
of cells on collagen I-treated plates prior to tamoxifen
induction offered the most robust differentiation into
myotubes based on morphological appearance. Matri-
gel overlay was applied when cells reached conflu-
ence, and this was followed by tamoxifen induction in
DMEM with 10 % FBS (2.5 μM, 24–48 h), and
culture in HD media for the indicated time course.
The outline for this optimized protocol is depicted in
Fig. 3a.
MyoD controls temporal expression of early and late
genes in muscle development through a feed-forward
mechanism [33]. To characterize myogenic marker ex-
pression, we tested tamoxifen-treated iMyoD cells by
RT-PCR. Robust and sustained expression of MYOG
(myogenin) and MYH3 (embryonic myosin) was ob-
served (Fig. 3b). In addition, there was a temporal in-
crease in expression of ACTN2 (α-actinin) and DMD
(dystrophin) (Fig. 3b). Expression of MYH2, the adult
Fig. 1 Transduction of urine-derived cells (UDCs) with an iMyoD lentiviral construct for myogenic reprogramming. a General overview for generating
in vitro model of human skeletal muscle using UDCs and iMyoD construct. The cells were first isolated from urine samples and then transduced with
lentivirus encoding an inducible MyoD. The construct includes a 4-hydroxytamoxifen (tamoxifen, TAM) response element from the estrogen receptor (ERt)
downstream of the basic helix loop helix (bHLH) DNA binding domain of MyoD. After induction with tamoxifen, cells were placed in differentiation media.
b Bright-field images of isolated urine cell cultures at passage 3. Scale bar= 25 μm. c Images of immunolabeled MyoD (red) in UDCs after transduction with
the iMyoD lentivirus, and iMyoD-transduced urine cells treated with tamoxifen (5 μM, 48 h). Nuclei were marked with Hoechst 33342 (blue). Scale bar=
100 μm. Inset images show increased MyoD localization to the nuclei after tamoxifen. Inset of tamoxifen-treated line 2 cells shows one nuclei with MyoD
localization (left) and one without (right). Inset scale bar= 25 μm. d Lentiviral iMyoD transduction efficiency across four control urine cell lines, shown as the
percent of MyoD-positive cells relative the total number of cells
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entiation was extended to the 28d time point (Fig. 3b).
Similarly, real-time PCR detected most transcripts after
7 days of differentiation, with sustained or moderately
increased expression over time (Fig. 3c). However, DMD
and MYH2 demonstrated greater temporal increases in
transcript expression as myogenic maturation progressed
(Fig. 3c). Evaluation of myotubes by immunofluores-
cence microscopy showed accumulation of α-actinin,
dystrophin, and fast myosin heavy chain (MHC), con-
cordant with the messenger RNA (mRNA) data. Expres-
sion of these muscle proteins was associated with
increased myotube formation, organization, and elong-
ation, indicative of myogenic differentiation and matur-
ation over time (Fig. 3d).
To further characterize iMyoD-directed myogenic
maturation of urine cells, we analyzed reprogrammed
cultures differentiated for 28 and 35 days. Low-
magnification bright-field images of tamoxifen-treated
iMyoD lines 2 and 11 demonstrated elongated myotubeformation after 28 days in HD differentiation media
(Fig. 4a) in which expression of α-actinin and dys-
trophin was observed throughout each fiber (Fig. 4a).
Spontaneously twitching myotubes were observed in a
subset of fields at both 28 and 35 days of culture, indi-
cating sarcomere formation and function (Additional
files 1 and 2: Movies S1 and S2). Sarcomere formation
was confirmed with expression of fast myosin, α-actinin,
and titin, each localized internally to sarcolemmal dys-
trophin expression and in the expected pattern (Fig. 4b).
These results demonstrated efficient myogenic reprogram-
ming, differentiation, and maturation of iMyoD-transduced
urine cells.
Direct reprogramming of urine cells to model muscular
dystrophy
The iMyoD reprogramming strategy was applied
to urine cells derived from two patients with Limb
Girdle Muscular Dystrophy type 2C (LGMD2C),
which results from loss of function mutations in the
Fig. 2 Tamoxifen-induced myogenic reprogramming of iMyoD-transduced UDCs. a RT-PCR time course evaluation of DES (desmin) mRNA expression
in two UDC lines (2 and 11). iMyoD-transduced cells were treated with or without tamoxifen (2.5 μM, 24 h) and then cultured in differentiation media
as indicated (7, 14, and 28 days). GAPDH mRNA expression is shown as a control. b Real-time semi-quantitative PCR results for DES mRNA expression in
urine cell lines 2 and 11. c Immunofluorescence microscopy of MyoD (red) and desmin (green) protein expression in iMyoD-transduced control lines 2
and 11, without tamoxifen treatment. In the uninduced state, MyoD demonstrated a cytoplasmic distribution, and no appreciable desmin expression
was observed. Nuclei (blue); Scale bar = 100 μm. d After induction, MyoD (red) became more nuclear concomitant with cytoplasmic desmin (green)
protein expression. Myotube elongation progressed over time in culture. Scale bar= 100 μm
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derived cells from each patient were successfully
transduced with the iMyoD lentivirus. Real-time
PCR analysis of tamoxifen-treated iMyoD LGMD2Ccells demonstrated successful reprogramming into
the myogenic lineage (Fig. 5b) associated with mor-
phological myotube formation (Fig. 5c). RT-PCR ana-
lysis demonstrated full-length SGCG transcript
Fig. 3 Myogenic differentiation and maturation of induced iMyoD UDCs. a Timeline for differentiation of iMyoD-transduced cells. b RT-PCR for myogenic
maturation markers in iMyoD-transduced line 2, with or without tamoxifen (2.5 μM, 24 h), and culture in differentiation media as indicated (7, 14, and
28 days). Myogenin (MYOG) and embryonic myosin heavy chain (MYH3) were the earliest markers detected. c Real-time semi-quantitative PCR results
demonstrated that dystrophin (DMD) and adult myosin heavy chain (MYH2) were detected with further differentiation. d Images of myogenic markers in
iMyoD-transduced line 2. Increased muscle marker expression over time was accompanied by myotube elongation. Nuclei (blue); Scale bar= 100 μm
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and truncated mutant SGCG transcript expression in
the reprogrammed iMyoD patient cells (Fig. 5a).
Sarcolemmal associated γ-sarcoglycan protein was ob-
served in control but not in LGMD2C cells, consist-
ent with their mutation status (Fig. 5d).
We applied the same iMyoD strategy to DMD urine
cells. The DMD patient harbored a frameshift deletionof exons 46 and 47 (ex46/47del) (Fig. 6a). RT-PCR
analysis demonstrated full-length DMD transcript
expression in reprogrammed control iMyoD cells and
truncated DMD mutant transcript expression in the
reprogrammed iMyoD patient cells (Fig. 6a). Sequence
analysis of the PCR-amplified transcripts confirmed the
deletion of exons 46 and 47 in the reprogrammed
patient-derived cells (Fig. 6b). Sarcolemma-associated
Fig. 4 Maturation of myotubes at 28-day and 35-day time points. a Bright-field images of myotube formation at the 28-day time point in iMyoD lines
2 and 11 after induction and differentiation (left panels). Middle panels show images of dystrophin (green) and α-actinin (red) protein expression, taken
in the same field as the bright-field panels. The right panels show the merged images revealing dystrophin and α-actinin expressions throughout the
lengths of the myotubes. Scale bar = 100 μm. b Images of iMyoD-induced UDCs after 35 days of differentiation showing expression of fast MHC,
α-actinin, and titin. The magnified region of interest (ROI) is outlined in the first panels (white rectangles). White arrows highlight the membrane
localization of dystrophin (green). White arrowheads highlight the formation of sarcomeres (red). Scale bar = 25 μm
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In contrast, dystrophin protein was not detected in
reprogrammed DMD patient cells after 28d differenti-
ation (Fig. 6c). Thus, the iMyoD strategy in urine
cells replicated the primary LGMD and DMD pheno-
types in vitro.
CRISPR/Cas9 mediated genome editing in single urine cell
clones
Finally, we evaluated CRISPR (clustered regularly inter-
spaced short palindromic repeats)/Cas9 (CRISPR-associ-
ated protein 9) mediated genome editing in urine cells.
For these studies, the goal was to introduce the mostcommon LGMD2C disease-causing mutation into con-
trol cell lines by deleting one thymine from SGCG exon
6 to disrupt the reading frame [26]. To generate the
521ΔT mutation, we used a gRNA targeting downstream
of five sequential thymine residues and a single-stranded
oligonucleotide (ssODN) to mediate homology-directed
repair (HDR). The ssODN targeting the minus strand
contained a synonymous G > A transition to disrupt the
protospacer adjacent motif (PAM) and introduce a
novel Alu1 restriction site (Fig. 7a). CRISPR compo-
nents were electroporated into control UDC lines 2
and 11, followed by FACS single cell sorting for GFP
into 96-well plates. Approximately 20 % of the
Fig. 5 Myogenic reprogramming of LGMD2C UDCs. a Schematic showing exon organization of the γ-sarcoglycan (SGCG) mRNA transcript and two
LGMD2C patients with frameshifting deletions affecting the SGCG locus that lead to premature stop codons (red triangles). One has a deletion of exons
5 and 6 (ex5/6del), and the other has a deletion of exon 7 (ex7del). RT-PCR demonstrated SGCG transcripts from UDCs after treatment with tamoxifen
(2.5 μM, 24 h) and culture in differentiation media for 28d. Orange arrowheads indicate the mutant transcripts lacking the expected exons. b Real-time
semi-quantitative PCR results demonstrate myogenic reprogramming of ex5/6del (top) and ex7del (bottom) after treatment with tamoxifen (2.5 μM,
24 h) and culture in differentiation media as indicated (7, 14, and 28 days). c Images of myogenic markers in iMyoD control and LGMD2C ex5/6del and
ex7del patient-derived lines. LGMD2C patient-derived cells formed myotubes comparable to those of control cells. Nuclei (blue); Scale
bar = 50 μm. d Desmin, α-actinin, dystrophin, and fast MHC were expressed in LGMD2C cells. γ-sarcoglycan (green) was not detected. White boxes
outline double-labeled regions of interest (ROI) enlarged in far right panels. Images show γ-sarcoglycan expression and localization to the membrane
in line 11, as opposed to no detectable expression of γ-sarcoglycan in LGMD2C patient myotubes. Scale bar= 100 μm in left and middle panels; 50 μm
in right panels
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ciently so that they could be evaluated for CRISPR-
mediated gene editing (Fig. 7b). The proliferation
capacity of FACS-sorted clones was similar in un-
treated cells and cells electroporated with the Cas9
GFP plasmid alone.
The genomic region including SGCG exon 6
was PCR amplified to analyze the results of gene edit-
ing. Restriction digest of the PCR products revealed
the presence of an Alu1 site in a subset of clones, in-
dicative of HDR repair (Fig. 7c). Sequence analysis
demonstrated efficient genome editing in UDCs with
the expected variety of both heterozygous andhomozygous mutations, including insertions and dele-
tions from nonhomologous end joining (NHEJ) repair
and specific point mutations directed by HDR (Fig. 7c,
d). Generation of clones with both heterozygous and
homozygous 521ΔT mutations was evident in line 2
(Fig. 7c, d). Interestingly, a subset of HDR-edited
clones contained a point mutation in the PAM region
without the upstream thymine deletion, suggesting
that this region is refractory to editing and/or re-
quired a gRNA target closer to the 5T region. A sum-
mary of the gene editing results is shown in Fig. 7b,
Additional file 3: Table S1 and S2, and Figure S1 and
S2. Collectively, these data demonstrated the ability to
Fig. 6 Myogenic reprogramming of DMD patient-derived urine cells. a Schematic showing organization of dystrophin exons 42 to 51 (top) and DMD
patient with a frameshift deletion of exons 46 and 47 (bottom). RT-PCR demonstrated DMD transcript expression from iMyoD-transduced line 11 control
and DMD ex46/47del mutant cell lines, after tamoxifen induction (2.5 μM, 24 h) and differentiation as indicated. Blue arrows indicate the location of the
outer primers that produce the PCR products in the gel below. Red arrows indicate nested primers used to generate transcripts used for sequencing.
b Sequencing results from RT-PCR products from iMyoD-reprogrammed urine-derived cells. The sequenced transcripts were generated from a set of
nested primers (red) shown in a. Line 11 showed the expected exon45-exon46 and exon47-exon48 junctions. The ex46/47del DMD individual shows the
out-of-frame mutant exon45-exon48 junction. c Immunofluorescence images of iMyoD line 17 and DMD ex46/47del cells labeled with dystrophin using
the NCL-DYSB antibody to dystrophin. The antibody to dystrophin showed membrane localization of dystrophin in control cells (top). No dystrophin was
detected in DMD patient-derived myotubes. Scale bar= 50 μm
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Cas9, generating single cell clones with a specific
point mutation.
Discussion
The limited availability of human skeletal muscle tissue
encumbers the study of muscle development and the
pathology of muscle disease. Many novel strategies have
been taken to overcome this limitation, relying on gen-
etic engineering with direct and indirect reprogramming
of cells. Regardless of strategy, a key component to
success is the initial cell source, specifically the ease
of acquisition and ability to reprogram. Urine is anunderutilized, noninvasive, and cost effective source of
primary human cells that has served as a platform for
urothelial-based culture and iPSC reprogramming
[19–21]. Recent advances in urine cell isolation have
generated clonal populations of autologous human
cells with a high proliferative capacity, evident tel-
omerase activity, and plasticity for reprogramming
into multiple lineages [20, 21]. These characteristics
make urine-derived cells an attractive source of
primary human cells for in vitro models. We now ex-
tended these findings showing that inducible expres-
sion of MyoD efficiently reprogrammed UDCs into
the myogenic lineage, providing a simple strategy to
Fig. 7 CRISPR/Cas9-mediated gene editing in UDCs. a Targeting strategy to introduce the 521ΔT point mutation into control SGCG exon 6
through gRNA guided, Cas9 nuclease generated double strand DNA break (DSB) with ssODN-mediated HDR repair. A portion of the SGCG exon 6
coding region is shown; a single T was removed from the 5T sequence region (cyan box). The downstream gRNA target sequence is highlighted
in blue, the PAM sequence in pink, and the Cas9 DSB indicated by a yellow triangle. Below it is a portion of the 142 bp ssODN HDR repair template
encoding the single T deletion along with a downstream G > A synonymous mutation (green) that destroys the PAM sequence and introduces an
Alu1 restriction site. b Summary of efficiency of CRISPR/Cas9 protocol. c Alu1 restriction digest of a PCR-amplified genomic region including SGCG
exon 6 and the flanking intronic sequences. d Left, partial summary of the Sanger sequencing results from individual line 2 edited clones. Right,
the DNA trace from an unedited control and a clone with a homozygous deletion of a single T from the 5T of SGCG exon 6, recreating the most
common LGMD2C mutation
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virtually any human subject.
Urine cells demonstrate an inclination towards the
mesodermal lineage. A subpopulation of cells, classified
as urine stem cells, express pericyte and mesenchymal
stem cell markers and were able to differentiate into
podocytes, smooth muscle, and urothelial cells [20, 21, 32].
The ability of UDCs to differentiate into skeletal muscle
is less defined. Studies showed growth on specific bio-
materials, presence of specific growth factors, or defined
media modifications promoted expression of myogenic
markers such as MyoD, desmin, and myosin [23, 34].However, these cells were not observed to form stria-
tions nor to display contractile properties. Given the
known expression of these markers, it is possible that
without sufficient MyoD, UDCs differentiate more to-
wards smooth rather than striated muscle lineages [21].
The strategy with an induced MyoD pulse combined
with media manipulation drove urine cells through the
initial stages of myogenic development into a more ma-
ture phenotype, complete with expression of dystrophin,
adult myosin, titin, and γ–sarcoglycan, along with the
presence of functional sarcomeres. Despite these ad-
vancements, this cellular model still lacks major
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bules and resident stem cell niches.
An alternative strategy to direct reprogramming with
MyoD would be to first reprogram UDCs into iPSCs and
then use the iPSC lines for myogenic differentiation. This
approach has the advantage of iPSC self-renewal, although
immortalization of UDCs directly could obviate this need
in vitro. DMD UDCs were previously successfully repro-
grammed into iPSC and differentiated into cardiomyo-
cytes, recapitulating cardiac phenotypes in vitro [4].
Skeletal muscle differentiation of iPSCs has proven
more challenging, although more efficient skeletal
muscle differentiation from iPSC using small molecules
has recently been reported [7]. Interestingly, the ease of
urine cell isolation, transduction with iMyoD virus, and
reprogramming into iPSC suggest an ability to employ
multiple parallel models for the study of muscle disease.
A summary of cell types for modeling muscle disease
and the timeline for generating these models in culture
is shown in Fig. 8.
We also showed that UDCs can be directly gene edited
using CRISPR/Cas9 technology. The use of gene editingFig. 8 Overview of options for modeling skeletal muscle disease in cell culture.
urine, and blood. Myoblasts cultured from muscle biopsies require approximate
myotube differentiation [46–48]. Primary dermal fibroblasts isolated from skin bi
transduced with inducible MyoD (iMyoD) lentivirus, expanded, and differentiate
to 4 weeks for expansion and a similar time frame for iMyoD-induced myotube
typically transformed using Epstein-Barr virus (EBV) to generate lymphoblastoid
and LCLs can all be reprogrammed to induced pluripotent stem cells (iPSCs). O
measures such as immunofluorescence for pluripotency markers, karyotyping, a
As each laboratory has its own quality control measures, this process will add va
can be readily differentiated into cardiomyocytes [4, 49, 50]. Improved efficiency
advances are expected to enhance the efficiency of this process [6, 7]for muscle disease has focused intently on genetic cor-
rection strategies with significant success on the study of
muscular dystrophy, as recent studies showed the ability
to correct DMD disease-causing mutations in animal
models and human cells [35–43]. However, the ability to
insert mutations of interest is also useful since it allows
the study of disease models without the need to access
patients directly. Nevertheless, gene editing in human
iPSCs is challenged by the availability of patient cell
lines, isolation of pure clonal populations, and low edit-
ing efficiency, especially when targeting precise muta-
tions with homology-dependent repair [29, 44, 45].
While some technical aspects of the CRISPR/Cas9 sys-
tem are still undergoing improvement, the relative ease
of urine cell isolation, coupled with the ability to gener-
ate single cell clones, makes this an attractive primary
cell platform for CRISPR/Cas9 gene editing.
Conclusions
Here, we showed that direct reprogramming of urine
cells using MyoD is feasible from patients with muscle
disease and can recapitulate the basic disease phenotype.Primary cell sources for establishing cell cultures include the muscle, skin,
ly 3 to 4 weeks for expansion and an additional 2 weeks of culture for
opsies require 3 to 4 weeks for expansion. Fibroblasts can then be
d to yield myotubes by approximately 8 weeks [12, 14]. Urine cells require 3
formation as dermal fibroblasts. Lymphocytes isolated from blood are
cell lines (LCLs), which requires 3 to 4 weeks. Fibroblasts, urine-derived cells,
nce generated and expanded, iPSCs will be subjected to quality control
nd embryoid body formation or teratoma formation for three germ layers.
riable amount of time for iPSC culture (indicated by hatch marks). iPSCs
for myotube differentiation from iPSCs has been reported, but additional
Kim et al. Skeletal Muscle  (2016) 6:32 Page 15 of 16Because urine cells are readily available and collected
noninvasively, this approach provides a highly useful
model of human muscle disease.
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